AMCP will occasionally publish highlights from AMCP and other conferences designed for those in managed care pharmacy. Highlights include summaries of select featured sessions and posters. Meetings published currently include the AMCP Annual 2023, Psych Congress 2023, and the American Psychiatric Association 2023 Annual Meeting.
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. On April 27, AMCP convened an expert panel of clinical and managed care stakeholders to increase understanding on how payers can inform strategies to improve the care and treatment of those impacted by ALS.
Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
